Results 41 to 50 of about 11,992 (201)
The objectives of this study were to do a survey of the autoimmune skin diseases and update the records regarding the occurrence of discoid lupus erythematosus in canine and feline populations attended at the Dermatology Service of the College of ...
Jéssica Correa Rodrigues +4 more
doaj +1 more source
Hypertrophic discoid lupus erythematosus
Hypertrophic discoid lupus erythematosus is a distinct form of chronic cutaneous (discoid) lupus, which is characterized by hyperkeratotic plaques that typically are observed over the face, arms, and upper trunk. We present the case of a 43-year-old man with verrucous plaques that were distributed symmetrically over the face, who initially was treated ...
Farley-Loftus, Rachel +4 more
openaire +4 more sources
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease with which a variety of neuropathic disorders have been associated. Among these, the acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barre syndrome has ...
Cevik, S. +3 more
core +1 more source
Objective This research article aims to describe the prevalence, associations, and health‐related quality of life (HRQoL) impact of mucocutaneous features of systemic lupus erythematosus (SLE). Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analyzed (2013–2021).
Amanda M. Saracino +42 more
wiley +1 more source
Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific mucocutaneous manifestations in patients with systemic lupus ...
Jun Kang, Aaron Bao
doaj +1 more source
Wasin Saowaluksakul,1 Chutima Seree-aphinan,1 Suthinee Rutnin,1 Kochawan Boonyawat,2 Kumutnart Chanprapaph1 1Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Division of ...
Saowaluksakul W +4 more
doaj
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
A 61-year-old female with systemic lupus erythematosus presented with refractory discoid lupus. Despite treatment with numerous immunosuppressive therapies, including prednisone, hydroxychloroquine and mycophenolate mofetil, her cutaneous lupus remained ...
Abdullah Ramadhan +3 more
doaj +1 more source
Antimalarials and the eye [PDF]
Following the first reports in 1954 of the beneficial effects of chloroquine in cases of lupus erythematosus, this drug and its numerous derivatives have been used extensively in the treatment of systemic and discoid lupus erythematosus and rheumatoid ...
Coleiro, Joseph A.
core
Recalcitrant Eyelid Lupus Treated With Topical Ruxolitinib
ABSTRACT Lupus of the eyelids, or lupus blepharitis, is a rare and localized form of chronic cutaneous lupus. The use of topical corticosteroids is limited in this sensitive area due to the risk of adverse events. We present a case of eyelid lupus, with histological confirmation, resistant to multiple lines of treatment, successfully treated with ...
Clémence Bertold +6 more
wiley +1 more source

